Bavarian Nordic to Host First Quarter 2017 Results Conference Call
(Thomson Reuters ONE) -
COPENHAGEN, Denmark - April 27, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) will announce its 2017 first quarter results on Thursday, May 4, 2017.
The management of Bavarian Nordic will host a conference call at 2:00 pm CEST
(8:00 am EDT) on the same day to present the interim results followed by a Q&A
session.
Dial-in numbers for the conference call are: Denmark: +45 32 71 16 60, UK: +44
(0) 20 3427 1911, USA: +1 646 254 3364. Participant code is 7659153.
A live and archived webcast of the call and relevant slides will be available at
http://bit.ly/2popqvJ.
Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications.
Phone +45 61 77 47 43
U.S.: Seth Lewis, Vice President, Investor Relations & Communications. Phone:
+1 978 341 5271
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the
development, manufacturing and commercialization of cancer immunotherapies and
vaccines for infectious diseases, based on the Company's live virus vaccine
platform. Through long-standing collaborations, including a collaboration with
the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for
infectious diseases, including the non-replicating smallpox vaccine,
IMVAMUNE(®), which is stockpiled for emergency use by the United States and
other governments. The vaccine is approved in the European Union (under the
trade name IMVANEX(®)) and in Canada. Bavarian Nordic and its partner Janssen
are developing an Ebola vaccine regimen, which has been fast-tracked, with the
backing of worldwide health authorities, and a vaccine for the prevention and
treatment of HPV. Additionally, in collaboration with the National Cancer
Institute, Bavarian Nordic has developed a portfolio of active cancer
immunotherapies, including PROSTVAC(®), which is currently in Phase 3 clinical
development for the treatment of advanced prostate cancer. The company has
partnered with Bristol-Myers Squibb for the potential commercialization of
PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on
Twitter (at)bavariannordic.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 27.04.2017 - 17:30 Uhr
Sprache: Deutsch
News-ID 538883
Anzahl Zeichen: 2773
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 136 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic to Host First Quarter 2017 Results Conference Call"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
